Stockholm, Sweden

Charlotta Berghard

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Charlotta Berghard

Introduction: Charlotta Berghard, a prominent inventor based in Stockholm, Sweden, has made significant strides in the field of biopharmaceuticals. With a total of five patents to her name, her work primarily revolves around polypeptides that interact with human complement C5, showcasing her dedication to innovation and therapeutic applications.

Latest Patents: Among her latest inventions are the polypeptides binding to human complement C5. These inventions relate to polypeptides that include a specific C5 binding motif, characterized by an amino acid sequence comprising EXXXA XXEID XLPNL XXXQW XAFIXXLXD, as well as sequences that maintain at least 86% identity to the original sequence. The therapeutic potential of these polypeptides is substantial, as they are designed for treatment of C5 related conditions, thereby contributing to advancements in medical science.

Career Highlights: Throughout her career, Charlotta has worked with esteemed companies in the biopharmaceutical sector. Notably, she has been affiliated with Swedish Orphan Biovitrum AB and IPC Research, LLC. Her role in these organizations has allowed her to push the boundaries of science and technology, leading to her successful patent applications.

Collaborations: Collaboration has been a key aspect of Charlotta Berghard's work. She has partnered with talented individuals such as Magnus Berglund and Patrik Strömberg, leveraging their expertise to enhance her inventions and research. Their teamwork exemplifies the collaborative spirit that drives innovation in the scientific community.

Conclusion: Charlotta Berghard is a remarkable inventor whose contributions are paving the way for new therapeutic approaches through her work with complement C5 binding polypeptides. Her dedication to innovation in the field of biopharmaceuticals reflects her commitment to improving patient outcomes and advancing medical science. With her impressive portfolio of patents and successful collaborations, she continues to be an influential figure in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…